Tempest Therapeutics to Acquire Factor Bioscience Dual-CAR T Programs in All-Stock Deal
I'm PortAI, I can summarize articles.
Tempest Therapeutics, Inc. is set to acquire dual-CAR T programs from Factor Bioscience in an all-stock deal, adding TPST-2003 to its pipeline. The transaction, pending stockholder approval, is expected to close in early 2026. Post-acquisition, Matt Angel will become President and CEO, and Stephen Brady will be Chairman. The deal includes an investment commitment from Factor to support operations through mid-2027.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments